Get more Mail & Guardian
Subscribe or Login.

Fake, dodgy drugs drive malaria crisis in Africa

Hopes of controlling malaria in Africa could be wrecked by criminals who are circulating counterfeit and substandard drugs, threatening millions of lives, scientists are warning.

They are calling for public health authorities to take urgent action to preserve the efficacy of the anti-malarials now being used in the worst-hit areas of the continent.

There has been growing hope of an end to the age-old scourge of malaria, with UN and donor countries having contributed to a massive effort to get modern technological tools to endemic areas, including insecticide-impregnated bed nets and new drugs that had their origins in China, derived from artemisinin plants.

Artemisinins have replaced old medicines such as chloroquine and mefloquine in places where the malaria parasite has developed resistance. It is the common fate of anti-malarials, which is why the World Health Organisation (WHO) has urged that the artemisinins should only be used in combination with other drugs, which delays resistance developing.

But large parts of Africa are threatened by the distribution of fake and poor quality anti-malarials made illicitly in China.


Drug-resistant parasites
Malaria kills nearly a million people each year, mainly young children and pregnant women. It is caused by parasites injected into the bloodstream by mosquitoes.

Some of the fake drugs contain artemisinin, but not enough to kill all the parasites in a child’s body. Not only will the child struggle to recover, but the parasites that survive may become resistant to the drug and spread a form of the disease that ACTs (artemisinin combination therapy) will no longer cure.

In a study in the Malaria Journal, Dr Paul Newton from the Wellcome Trust-Mahosot Hospital-Oxford University Tropical Medicine Research Collaboration in Laos and a team of colleagues report on the make-up of some of the fake anti-malarials on sale in Africa, as well as some that are equally useless and dangerous because they are of poor quality. They looked at samples of suspect drugs from 11 countries collected between 2002 and 2010.

Analysis showed some counterfeits contained a mixture of wrong active pharmaceutical ingredients, some of which may initially alleviate malaria symptoms but would not cure malaria. Worse still, these unexpected ingredients could cause potentially serious side effects, particularly if they were to interact with other medication that the patient was taking, such as anti-retroviral therapies for HIV.

The fake drugs appear to have been made in east Asia. The researchers identified pollen from that region in some of the tablets. In 2001, police in Guangzhou, China, arrested Nigerian and Chinese men for production of counterfeits of the anti-malarial halofantrine. There was no evidence from the pollen analysis to suggest any of the drugs would have been manufactured in Africa, but production facilities for packaging materials for counterfeit anti-malarials have been seized in Nigeria.

‘Enormous investment’
It is impossible to say how widely counterfeit and substandard drugs are being distributed, but, Newton said something needed to be done. “The enormous investment in the development, evaluation and deployment of anti-malarials is wasted if the medicines that patients actually take are, due to criminality or carelessness, of poor quality and do not cure,” he said.

“Malaria can be readily treated with the right drugs of good quality, but poor quality medicines, as well as increasing mortality and morbidity, risk exacerbating the economic and social impact of malaria on societies that are already poor.”

Newton and his team have called urgent action from public health authorities to prevent the circulation of the fake and ineffective drugs and also to stop artemisinin being used on its own, which makes it far more likely that resistance will develop than if it is in combination.

It will be very hard for the affected African countries to tackle the problem, however.

“It is very difficult to regulate the drug supply in poor countries,” he said. “WHO has said that 30% of drug regulatory authorities don’t function. They don’t list which they are but logically they are likely to be in economically poor, malarious countries. It is very difficult for them to control the import or introduction of artemisinin therapies.” —

Subscribe to the M&G

These are unprecedented times, and the role of media to tell and record the story of South Africa as it develops is more important than ever.

The Mail & Guardian is a proud news publisher with roots stretching back 35 years, and we’ve survived right from day one thanks to the support of readers who value fiercely independent journalism that is beholden to no-one. To help us continue for another 35 future years with the same proud values, please consider taking out a subscription.

Related stories

Advertising

Subscribers only

Khoikhoi versus US giant Amazon

The controversial River Club development gets the go-ahead, but opponents say they are heading for court

SIU moves on eThekwini housing scam

The developer allegedly secured illegal funding from the housing regulatory authority

More top stories

Why South Africa stopped making vaccines

The high demand for Covid vaccines means there is a limited global supply. Local manufacturing is one solution. So why isn’t South Africa making its own jabs?

‘He can’t just write letters out of anger’: Mantashe reacts...

That is not how decisions are made in an organisation, the party’s national chairperson warns as Magashule sends suspension letter to Ramaphosa

Hlophe’s attorney found in contempt of court

The high court said Barnabas Xulu acted with impunity and contempt in the saga of getting him to repay millions in state funds

Aced: ANC secretary general suspended from the party for the...

Magashule is barred from carrying out his tasks and cannot talk on behalf of the party
Advertising

press releases

Loading latest Press Releases…
×